L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates

By Kuoppamäki M.   Al-Barghouthy G.   Jackson M. J.   Smith L. A.   Quinn N.   Jenner P.  

Journal of Neural Transmission, Vol. 114, Iss. 9, 2007-09 ,pp. : 1147-1153

Springer Publishing Company

Access to resources Recommend Favorite

Cholinergic manipulation of motor disability and l-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets

By Jackson M.   Swart T.   Pearce R.   Jenner P.  

Journal of Neural Transmission, Vol. 121, Iss. 2, 2014-02 ,pp. : 163-169

Springer Publishing Company

Access to resources Recommend Favorite

Affective symptomatology in schizophrenia: a risk factor for tardive dyskinesia?

By Schulze T.G.   Muller D.J.   Krauss H.   Marwinski K.   Maroldt A.-O.   Novo y Fernandez A.   Fimmers R.   Held T.   Maier W.   Nothen M.M.   Rietschel M.  

European Psychiatry, Vol. 16, Iss. 1, 2001-02 ,pp. : 71-74

Elsevier

Access to resources Recommend Favorite

Focus on Lower Risk of Tardive Dyskinesia with Atypical Antipsychotics

By Nasrallah Henry  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 18, Iss. 1, 2006-01 ,pp. : 57-62

Informa Healthcare

Access to resources Recommend Favorite

Tardive dyskinesia due to risperidone

By Sakkas P.   Liappas J.   Christodoulou G.  

European Psychiatry, Vol. 13, Iss. 2, 1998-01 ,pp. : 107-108

Elsevier

Access to resources Recommend Favorite